Taysha Gene Therapies (TSHA)
(Real Time Quote from BATS)
$2.04 USD
+0.02 (0.99%)
Updated Oct 2, 2024 03:00 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Balance Sheet
Fiscal Year End for Taysha Gene Therapies, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 144 | 88 | 149 | 251 | 0 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 5 | 9 | 11 | 7 | 0 |
Total Current Assets | 150 | 96 | 160 | 258 | 0 |
Net Property & Equipment | 11 | 15 | 51 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 1 | 1 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 4 | 3 | 0 | 0 |
Total Assets | 173 | 126 | 214 | 259 | 0 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 6 | 11 | 22 | 2 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 12 | 18 | 30 | 5 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 18 | 34 | 0 | 0 | 0 |
Total Current Liabilities | 37 | 63 | 52 | 7 | 0 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 41 | 38 | 37 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 2 | 4 | 30 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 98 | 125 | 119 | 8 | 0 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 588 | 402 | 331 | 312 | 1 |
Retained Earnings | -513 | -401 | -236 | -61 | -1 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 75 | 1 | 95 | 251 | 0 |
Total Liabilities & Shareholder's Equity | 173 | 126 | 214 | 259 | 0 |
Total Common Equity | 75 | 1 | 95 | 251 | 0 |
Shares Outstanding | 186.90 | 62.40 | 38.40 | 37.70 | NA |
Book Value Per Share | 0.40 | 0.02 | 2.48 | 6.67 | 0.00 |
Fiscal Year End for Taysha Gene Therapies, Inc falls in the month of December.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 173 | 124 | 144 | 164 | 45 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 5 | 6 | 5 | 8 | 9 |
Total Current Assets | 178 | 131 | 150 | 172 | 54 |
Net Property & Equipment | 11 | 11 | 11 | 11 | 14 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 2 | 2 | 3 | 3 |
Total Assets | 200 | 153 | 173 | 196 | 82 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 9 | 10 | 6 | 8 | 11 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 12 | 14 | 12 | 14 | 20 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 14 | 15 | 18 | 159 | 20 |
Total Current Liabilities | 34 | 39 | 37 | 180 | 51 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 3 | 6 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 38 | 41 | 41 | 39 | 38 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 2 | 4 | 4 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 92 | 99 | 98 | 245 | 119 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 664 | 591 | 588 | 512 | 407 |
Retained Earnings | -558 | -537 | -513 | -561 | -444 |
Other Equity | 2 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 109 | 54 | 75 | -49 | -37 |
Total Liabilities & Shareholder's Equity | 200 | 153 | 173 | 196 | 82 |
Total Common Equity | 109 | 54 | 75 | -49 | -37 |
Shares Outstanding | 187.00 | 187.00 | 186.90 | 186.90 | 64.20 |
Book Value Per Share | 0.58 | 0.29 | 0.40 | -0.26 | -0.58 |